Medpace Holdings, Inc. Q2 FY26 Results

Summary

Medpace Holdings, Inc. reported robust financial results for the second quarter of 2026, with revenue increasing 17.2% year-over-year to $707.3 million. The company saw strong growth in net new business awards, up 28.2% to $795.7 million, leading to a net book-to-bill ratio of 1.13x. GAAP net income rose significantly to $121.4 million ($4.25 per diluted share) from $90.3 million ($3.10 per diluted share) in the prior year, while EBITDA grew 17.6% to $153.4 million. The company also provided a positive outlook, forecasting full-year 2026 revenue between $2.805 billion and $2.885 billion.

Key Highlights

1. 1

   Revenue for the second quarter of 2026 increased by 17.2% to $707.3 million, compared to $603.3 million in the prior-year period.

2. 2

   Net new business awards reached $795.7 million in Q2 2026, a 28.2% increase from the prior year, resulting in a net book-to-bill ratio of 1.13x.

3. 3

   GAAP net income for the second quarter of 2026 was $121.4 million, or $4.25 per diluted share, up from $90.3 million, or $3.10 per diluted share, in Q2 2025.

4. 4

   EBITDA increased by 17.6% to $153.4 million in the second quarter of 2026, compared to $130.5 million in the prior-year period.

5. 5

   The company generated $162.0 million in cash flow from operating activities during the second quarter of 2026.

6. 6

   Backlog as of June 30, 2026, increased 4.9% to $3,014.2 million from the comparable prior-year period.

7. 7

   Full year 2026 revenue is forecasted to be in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025.